(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of -1.13% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Becton Dickinson & Co's revenue in 2026 is $21,366,000,000.On average, 18 Wall Street analysts forecast BDX's revenue for 2026 to be $5,350,168,471,059, with the lowest BDX revenue forecast at $5,176,302,461,622, and the highest BDX revenue forecast at $5,590,715,263,830. On average, 18 Wall Street analysts forecast BDX's revenue for 2027 to be $5,493,449,493,099, with the lowest BDX revenue forecast at $5,280,181,202,601, and the highest BDX revenue forecast at $5,850,274,346,064.
In 2028, BDX is forecast to generate $5,704,513,460,181 in revenue, with the lowest revenue forecast at $5,384,059,943,580 and the highest revenue forecast at $6,147,306,926,370.